Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.
Read More
Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer.
Read More
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Read More
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
Read More
MSD’s Keytruda will be routinely available on the NHS for specific patients with previously untreated metastatic non-small-cell lung cancer, after NHS England struck a deal with the company, endorsed by NICE, to ensure its cost-effectiveness.
Read More
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
Read More
Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.
Read More
US regulators have green-lighted the use of Novartis Zykadia as a first-line treatment option for some patients with non-small cell lung cancer.
Read More
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.
Read More
US regulators are undertaking a speedy review of Novartis’ application to expand the use of Zykadia to include its first-line use in patients with ALK positive non small cell lung cancer (NSCLC).
Read More
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis’ Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Read More
US regulators have issued a green light for first-line use of Merck’s immunotherapy Keytruda to treat patients with certain forms of lung cancer.
Read More
